HSPA9 and melanoma: In vemurafenib-resistant BRAF-mutant melanoma cells, HSPA9 depletion triggers cell death in a MEK/ERK- and ANT/CypD-dependent manner, indicating that HSPA9 is an effective target in drug-resistant tumors [105].